

Funding

This study was supported by the Medical Science and Technology Research Program of Henan Province (No. 2018020042).

Conflicts of interest

None.

References

1. Merrett ND, Wilson RB, Cosman P, Biankin AV. Superior mesenteric artery syndrome: diagnosis and treatment strategies. *J Gastrointest Surg* 2009;13:287–292. doi: 10.1007/s11605-008-0695-4.
2. Mandarray MT, Zhao L, Zhang C, Wei ZQ. A comprehensive review of superior mesenteric artery syndrome. *Eur Surg* 2010;42:229–236. doi: 10.1007/s10353-010-0561-y.
3. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308–328. doi: 10.1038/ajg.2012.444.
4. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, *et al.* Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. *Am J Gastroenterol* 2001;96:52–57. doi: 10.1016/S0002-9270(00)02244-9.
5. Yang WL, Zhang XC, Zhang WF, Yan CQ, Wang FJ, Ma YL. Selection and evaluation of surgical treatment for superior mesenteric artery syndrome. *Chin J Gastrointest Surg* 2007;10:288–290. doi: 10.3760/cma.j.issn.1671-0274.2007.03.030.
6. Dekonenko C, Hill JA, Sobrino JA, Snyder CL, Oyetunji TA. Ligament of Treitz release with duodenal lowering for pediatric superior mesenteric artery syndrome. *J Surg Res* 2020;254:91–95. doi: 10.1016/j.jss.2020.04.006.

How to cite this article: Zhang R, Li ZT, Han XW, Liang LD, Wang ZG, Ji F. Diagnosis and treatment of superior mesenteric artery compression syndrome complicated with gastroesophageal reflux disease. *Chin Med J* 2021;134:1382–1384. doi: 10.1097/CM9.0000000000001430

Corrigendum

Corrigendum: Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study

DOI: 10.1097/CM9.0000000000001482

In the article “Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study” which appeared in vol.130, issue 14, page 1655 of *Chinese Medical Journal*,^[1] “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA), and domestic sirolimus–eluting stents (Firebird2, MicroPort Medical, China).” should be corrected as “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird and Firebird2, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA).” The original results and conclusions are not affected.

Reference

1. Liu R, Xiong F, Wen Y, Ma YL, Yao Y, Gao Z, *et al.* Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study. *Chin Med J* 2017;130:1654–1661. doi: 10.4103/0366-6999.209904.